Table 3.
Mortality among patients with E. coli or Klebsiella spp. bacteremia treated empirically with different antimicrobials depending on the adequacy
| Adequate | Inadequate | p | RR (95% CI) | |
|---|---|---|---|---|
| Beta-lactam/Beta-lactam inhibitor combinations (n = 117) |
11 (13.1) |
13 (39.4) |
0.002 |
0.58 (0.37-0.91) |
| Amoxicillin/clavulanate (n = 67) |
3 (7.5) |
10 (37) |
0.004 |
0.34 (0.12-0.92) |
| Piperacillin/tazobactam (n = 50) |
8 (18.2) |
3 (50) |
0.11 |
0.79 (0.54-1.14) |
| Quinolones (n = 62) |
0) |
10 (20.4) |
- |
- |
| Carbapenem (n = 70) |
18 (25.7) |
- |
- |
- |
| Cefotaxime or ceftriaxone (n = 50) |
- |
7 (14) |
- |
- |
| Aminoglycoside monotherapy* (n = 22) |
3 (23.1) |
2 (22.2) |
0.68 |
1.02 (0.45-2.31) |
| None antimicrobial (n = 25) |
- |
7 (28) |
- |
- |
| Overall (n = 387) | 34 (17.2) | 47 (24.9) | 0.04 | 0.78 (0.59-1.03) |
Date are no. (%) of patients. *Patients with only aminoglycoside as empirical antibiotic ESBL-E susceptible.